Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Burning Rock CDx Test Enters Chinese Priority Approval Process

12 October 2026 · By · Wire by Fusion42

Published

12 October 2026

Topic

operational-macro

◆ Sectors

Diagnostics

◆ Geography

China

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 12 October 2026 · Fusion42 review

Burning Rock Biotech’s OncoCompass Target CDx Kit has entered China’s National Medical Products Administration priority approval process for medical devices.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it between 10 Oct 2026 and 12 Oct 2026.

◆ ◆ The Wire takeaway

China’s priority approval of this test opens faster market access for liquid biopsy diagnostics. You can now plan to engage with Chinese regulatory pathways more aggressively.

◆ Coverage

2 sources · first reported 10 Oct 2026 · latest 12 Oct 2026

◆ Related on Wire

◆ Topics

Diagnosticsliquid-biopsycdxregulatory-approvalchinanmpa